The European Parliament’s Special Committee on Covid-19 heard from representatives of companies that have developed vaccines against Covid-19 authorised in the European Union.
Dr Rudolf Ertl, Senior Vice President of Commercial Operations at Gilead, outlined the steps the company took when SARS-CoV-2 emerged. Mr Ertl described Covid-19 as a complex disease. He assessed the European approach favourably: “This is the approach that allows us to deal with this type of challenge”, he said,...